Prolactin-induced protein is required for cell cycle progression in breast cancer

Neoplasia (United States)

Volumn 16, Issue 4, 2014, Pages 329-342.e14

  Naderi, Ali ^a   Vanneste, Marion ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; ACTIN RELATED PROTEIN 2-3 COMPLEX; BETA TUBULIN; BETA1 INTEGRIN; BUB1 RELATED PROTEIN; CYCLIN B1; CYCLIN D1; FORKHEAD BOX M1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; PROLACTIN; PROLACTIN INDUCED PROTEIN; TALIN; TUMOR MARKER; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLYCOPROTEIN; PIP PROTEIN, HUMAN; PROTEIN BINDING;

ANEUPLOIDY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINESIS; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MCF 7 CELL LINE; MICROARRAY ANALYSIS; MICROTUBULE ASSEMBLY; MITOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEOMICS; TISSUE MICROARRAY; BREAST TUMOR; CELL CYCLE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROTUBULE; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANEUPLOIDY; ANTIGENS, CD29; BREAST NEOPLASMS; CARRIER PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; CYTOKINESIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULES; MITOSIS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN MULTIMERIZATION; TRANSCRIPTION, GENETIC;

EID: 84903999187     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.04.001     Document Type: Article

References (63)

1. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N,Vary CP,ColeDJ, andWatson PH (1999). The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer 81, 1002-1008.
2. Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO, Aparicio S, Brenton JD, and Caldas C (2006). A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 7, R101.
3. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, and Gerald WL (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008.
4. Baniwal SK, Chimge NO, Jordan VC, Tripathy D, and Frenkel B (2013). Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One 8, e62361.
5. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, and Goldstein D, et al. (2005). Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660-4671.
6. Naderi A and Hughes-Davies L (2008). A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10, 542-548.
7. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, and Bourstyn E, et al. (2013). Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 15, R37.
8. Carsol JL, Gingras S, and Simard J (2002). Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. Mol Endocrinol 16, 1696-1710.
9. Baniwal SK, Little GH, Chimge NO, and Frenkel B (2012). Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 227, 2276-2282.
10. Naderi A and Meyer M (2012). Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res 14, R111.
11. Caputo E, Manco G, Mandrich L, and Guardiola J (2000). A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 275, 7935-7941.
12. Gaubin M, Autiero M, Basmaciogullari S, Métivier D, Mis hal Z, Culerrier R, Oudin A, Guardiola J, and Piatier-Tonneau D (1999). Potent inhibition of CD4/TCR-mediated T cell apoptosis by a CD4-binding glycoprotein secreted from breast tumor and seminal vesicle cells. J Immunol 162, 2631-2638.
13. Schaller J, Akiyama K, Kimura H, Hess D, Affolter M, and Rickli EE (1991). Primary structure of a new actin-binding protein from human seminal plasma. Eur J Biochem 196, 743-750.
14. Cassoni P, Sapino A, Haagensen DE, Naldoni C, and Bussolati G (1995). Mitogenic effect of the 15-kDa gross cystic disease fluid protein (GCDFP-15) on breast-cancer cell lines and on immortal mammary cells. Int J Cancer 60, 216-220.
15. Naderi A, Liu J, and Bennett IC (2010). BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 126, 1596-1610.
16. Darzynkiewicz Z, Juan G, and Bedner E (2001). Determining cell cycle stages by flow cytometry. Curr Protoc Cell Biol 8.4, 1-18.
17. Naderi A, Liu J, and Francis GD (2012). A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. Int J Cancer 130, 71-82.
18. Rappsilber J, Mann M, and Ishihama Y (2007). Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2, 1896-1906.
19. Nesvizhskii AI, Keller A, Kolker E, and Aebersold R (2003). A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75, 4646-4658.
20. Leandro-García LJ, Leskelä S, Inglada-Pérez L, Landa I, de Cubas AA, Maliszewska A, Comino-Méndez I, Letón R, Gómez-Graña A, and Torres R, et al. (2012). Hematologic ß-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res 72, 4744-4752.
21. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, and Tong F, et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527.
22. Huang da W, Sherman BT, and Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
23. Huang da W, Sherman BT, and Lempicki RA (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13.
24. CheangMC, Chia SK, Voduc D, Gao D, Leung S, Snider J,WatsonM, Davies S, Bernard PS, and Parker JS, et al. (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101, 736-750.
25. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, and Lee KS (2010). Expression of androgen receptors in primary breast cancer. Ann Oncol 21, 488-492.
26. Villanueva J, Yung Y, Walker JL, and Assoian RK (2007). ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell 18, 1457-1463.
27. DiPaola RS (2002). To arrest or not to G2-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res., 8: 3512-3519, 2002. Clin Cancer Res 8, 3311-3314.
28. Chen X, Müller GA, Quaas M, Fischer M, Han N, Stutchbury B, Sharrocks AD, and Engeland K (2013). The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol 33, 227-236.
29. Dou Z, Ding X, Zereshki A, Zhang Y, Zhang J, Wang F, Sun J, Huang H, and Yao X (2004). TK kinase is essential for the centrosomal localization of TACC2. FEBS Lett 572, 51-56.
30. Tang Z, Shu H, Oncel D, Chen S, and Yu H (2004). Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol Cell 16, 387-397.
31. Westendorf JM, Rao PN, and Gerace L (1994). Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci U S A 91, 714-718.
32. Wolf WA, Chew TL, and Chisholm RL (1999). Regulation of cytokinesis. Cell Mol Life Sci 55, 108-120.
33. Fielding AB, Lim S, Montgomery K, Dobreva I, and Dedhar S (2011). A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells. Oncogene 30, 521-534.
34. Aszodi A, Hunziker EB, Brakebusch C, and Fässler R (2003). ß1 integrins regulate chondrocyte rotation, G1 progression, and cytokinesis. Genes Dev 17, 2465-2479.
35. Nieves B, Jones CW, Ward R, Ohta Y, Reverte CG, and LaFlamme SE (2010). The NPIY motif in the integrin beta1 tail dictates the requirement for talin-1 in outside-in signaling. J Cell Sci 123, 1216-1226.
36. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, and Parsons JT (1994). Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14, 1680-1688.
37. Sharp DJ, Rogers GC, and Scholey JM (2000). Microtubule motors in mitosis. Nature 407, 41-47.
38. Nolz JC, Medeiros RB, Mitchell JS, Zhu P, Freedman BD, Shimizu Y, and Billadeau DD (2007). WAVE2 regulates high-affinity integrin binding by recruiting vinculin and talin to the immunological synapse. Mol Cell Biol 27, 5986-6000.
39. Pelham RJ and Chang F (2002). Actin dynamics in the contractile ring during cytokinesis in fission yeast. Nature 419, 82-86.
40. Straight AF and Field CM (2000). Microtubules, membranes and cytokinesis. Curr Biol 10, R760-770.
41. Chuong SD,GoodAG, Taylor GJ, FreemanMC,MoorheadGB, andMuenchDG (2004). Large-scale identification of tubulin-binding proteins provides insight on subcellular trafficking, metabolic channeling, and signaling in plant cells. Mol Cell Proteomics 3, 970-983.
42. Royle SJ, Bright NA, and Lagnado L (2005). Clathrin is required for the function of the mitotic spindle. Nature 434, 1152-1157.
43. Zhou Q, Kee YS, Poirier CC, Jelinek C, Osborne J, Divi S, Surcel A, Will ME, Eggert US, and Müller-Taubenberger A, et al. (2010). 14-3-3 coordinates microtubules Rac, and myosin II to control cell mechanics and cytokinesis. Curr Biol 20, 1881-1889.
44. Sharp JA, Plant JJ, Ohsumi TK, Borowsky M, and Blower MD (2011). Functional analysis of the microtubule-interacting transcriptome. Molec Biol Cell 22, 4312-4323.
45. Atilla-Gokcumen GE, Castoreno AB, Sasse S, and Eggert US (2010). Making the cut: the chemical biology of cytokinesis. ACS Chem Biol 5, 79-90.
46. Meitinger F, Richter H, Heisel S, Hub B, Seufert W, and Pereira G (2013). A safeguard mechanism regulates Rho GTPases to coordinate cytokinesis with the establishment of cell polarity. PLoS Biol 11, e1001495.
47. Kops GJ, Weaver BA, and Cleveland DW (2005). On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5, 773-785.
48. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, and van Deursen JM (2007). Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J Cell Biol 179, 255-267.
49. Wierstra I (2013). The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res 118, 97-398.
50. Torres EM, Williams BR, and Amon A (2008). Aneuploidy: cells losing their balance. Genetics 179, 737-746.
51. Ricke RM, Jeganathan KB, and van Deursen JM (2011). Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation. J Cell Biol 193, 1049-1064.
52. Akoumianaki T, Kardassis D, Polioudaki H, Georgatos SD, and Theodoropoulos PA (2009). Nucleocytoplasmic shuttling of soluble tubulin in mammalian cells. J Cell Sci 122, 1111-1118.
53. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, and Pietenpol JA (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767.
54. Magklara A, Brown TJ, and Diamandis EP (2002). Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer 100, 507-514.
55. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, WangNJ, Ziyad S, and Tong F, et al. (2012). Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 109, 2724-2729.
56. Naderi A and Liu J (2010). Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett 298, 74-87.
57. Naderi A and Hughes-Davies L (2008). A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10, 542-548.
58. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, and Gerald WL (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008.
59. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, and Tong F, et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527.
60. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, HungMC, BonfiglioT, and HicksDG, et al. (2010).The expression patterns of ER, PR,HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 4, 35-41.
61. Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, and Bertucci F, et al. (2007). ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26, 7163-7169.
62. Lombardi DP (2004). The Tetraspanin Metastasis Suppressor Gene, KAI1/CD82, and the Proto-Oncogene, Her-2/neu, as Molecular Determinants of Metastasis in Breast Cancer Patients. Defense Technical Information Center Annual Summary Report, contract number DAMD17-03-1-0559, 1-29 (http://handle.dtic.mil/100.2/ADA433099).
63. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, and Neve RM, et al. (2009). Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15, 3654-3662.